We are monitoring the impact of COVID-19 on MEA Regenerative Medicines Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 243
Share on
Share on

Middle East & Africa Regenerative Medicine Market Research Report – Segmented By Product, Therapy, Application & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Analysis on Size, Share, COVID-19 Impact, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 243
Pages: 145

MEA Regenerative Medicine Market Size (2021 to 2026)

The size of the Middle East and Africa regenerative medicine market is poised to worth USD 7.08 billion by 2026 and USD 2.50 billion in 2021, growing at a CAGR of 23.15% from 2021 to 2026.            

Regenerative medicine is a branch of translational research that deals with replacing human or animal tissue with damaged tissue. In regenerative medicine, stem cells are used for the creation of a vaccine. There is a great rise in genetic diseases in the Middle East, such as sickle cell and thalassemia. The government and the Gulf Cooperation Council are collaborating to create awareness regarding regenerative medicine. The increasing demands for the new and improved quality regenerative vaccine are to propel the market's demand. The Emirates specialty hospital in Dubai opened the region's first regenerative medicine department. 

According to the WHO, the increasing rate of chronic diseases like cancer, heart diseases, and kidney failure will become the major cause of death by 2030. It is estimated that around 42% of deaths will be due to chronic diseases in this region. Increasing demand for improved healthcare solutions, rising funding from public & private organizations for the development of advanced healthcare solutions, and government initiatives to promote the development of regenerative medicine products are driving the growth of the regenerative medicine market in the Middle East and Africa.

However, an inadequate number of healthcare professionals, insufficient healthcare infrastructure, and low adoption of regenerative medicine products due to poor economic status are some of the factors restraining the growth of the regenerative medicine market in the Middle East and Africa. Regenerative medicine required a trained and skilled workforce to handle the process. Lack of training and education about regenerative medicine in the Middle East and Africa is impeding the market's growth rate. In addition, the cost of regenerative medicine is more where common people cannot afford is limiting the growth rate of the market. Fluctuations in the availability of raw materials may also hinder the growth rate of the regenerative medicine market.

Impact of COVID-19 on the MEA regenerative medicine market:

Rising cases of COVID-19 across the MEA countries are greatly influencing the market to grow. The scientists in the UAE have developed a treatment for COVID – 19 with the help of stem cells collected from the recovered patient and administrated by a nebulizer directly to the lungs. 

This research report on the MEA regenerative medicine market has been segmented and sub-segmented into the following categories:

By Product:

  • Cell-Based Products                            
    • Autologous Cell-Based Products
    • Allogeneic Cell-Based Products  
  • Acellular Products           

By Therapy: 

  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Immunotherapy

By Application: 

  • Orthopedic & Musculoskeletal Spine                           
  • Dermatology                          
  • Cardiovascular                       
  • Central Nervous System                   
  • Oncology                 
  • Diabetes                  
  • Other Applications

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the UAE is expected to account for the highest share in the Middle East and Africa regenerative medicine market during the forecast period. The number of clinical trials is increasing in this region. The government in this region is investing in promoting regenerative medicine to increase awareness. The rise in the scale of hospitals and clinics is propelling the growth rate of the market.

KEY MARKET PLAYERS:

Companies playing a prominent role in the MEA regenerative medicine market profiled in this report are Vertex Pharmaceuticals Incorporated (U.S.), Acelity L.P. Inc. (U.S.), Celgene Corporation (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), NuVasive, Inc. (U.S.), Vericel Corporation (Genzyme) (U.S.), Japan Tissue Engineering Co., Ltd. (Japan), Cytori Therapeutics Inc. (U.S.), Advantagene, Inc. (U.S.) and Mesoblast Ltd. (Australia).

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                       

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                    

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

5. Market Segmentation                                                              

                5.1 Introduction                                               

                5.2 Product                                        

                                5.2.1 Introduction                           

                                5.2.2 Cell-Based Products                            

                                                5.2.2.1 Autologous Cell-Based Products

                                                5.2.2.2 Allogeneic Cell-Based Products  

                                5.2.3 Acellular Products                

                5.3 Therapy                                       

                                5.3.1 Introduction                           

                                5.3.2 Cell Therapy                           

                                5.3.3 Gene Therapy                       

                                5.3.4 Tissue Engineering                               

                                5.3.5 Immunotherapy                   

                5.4 Application                                 

                                5.4.1 Introduction                           

                                5.4.2 Orthopedic & Musculoskeletal Spine                           

                                5.4.3 Dermatology                          

                                5.4.4 Cardiovascular                       

                                5.4.5 Central Nervous System                   

                                5.4.6 Oncology                 

                                5.4.7 Diabetes                  

                                5.4.8 Other Applications                               

6. Geographical Analysis                                                              

                6.5.1 Introduction                                           

                6.5.2 Middle East                                             

                6.5.2 South Africa                                            

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

8. Market Leaders' Analysis                                                        

                8.1 Vertex Pharmaceuticals Incorporated (U.S.)                                

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                             

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Acelity L.P. Inc. (U.S.)                                             

                8.3 Celgene Corporation (U.S.)                                 

                8.4 StemCells, Inc. (U.S.)                                              

                8.5 Organogenesis Inc.  (U.S.)                                    

                8.6 NuVasive, Inc. (U.S.)                                              

                8.7 Vericel Corporation (Genzyme) (U.S.)                                            

                8.8 Cytori Therapeutics Inc. (U.S.)                                            

                8.9 Advantagene, Inc. (U.S.)                                      

                8.10 Mesoblast Ltd. (Australia)                                  

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  2. Middle East & Africa Regenerative Medicines Market, By Product, From 2021 to 2026 (USD Billion)
  3. Middle East & Africa Cell-Based Products Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  4. Middle East & Africa Acellular Products Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  5. Middle East & Africa Regenerative Medicines Market, By Therapy, From 2021 to 2026 (USD Billion)
  6. Middle East & Africa Cell Therapy Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  7. Middle East & Africa Gene Therapy Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  8. Middle East & Africa Tissue Engineering Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  9. Middle East & Africa Immunotherapy Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  10. Middle East & Africa Regenerative Medicines Market, By Application, From 2021 to 2026 (USD Billion)
  11. Middle East & Africa Orthopedic & Musculoskeletal Spine Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  12. Middle East & Africa Dermatology Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  13. Middle East & Africa Cardiovascular Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  14. Middle East & Africa Central Nervous System Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  15. Middle East & Africa Oncology Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  16. Middle East & Africa Diabetes Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  17. Middle East & Africa Other Applications of Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  18. Middle East Regenerative Medicines Market, By Product, From 2021 to 2026 (USD Billion)
  19. Middle East Regenerative Medicines Market, By Therapy, From 2021 to 2026 (USD Billion)
  20. Middle East Regenerative Medicines Market, By Application, From 2021 to 2026 (USD Billion)
  21. Africa Regenerative Medicines Market, By Product, From 2021 to 2026 (USD Billion)
  22. Africa Regenerative Medicines Market, By Therapy, From 2021 to 2026 (USD Billion)
  23. Africa Regenerative Medicines Market, By Application, From 2021 to 2026 (USD Billion)
  24. Middle East & Africa Cell-Based Products Regenerative Medicines Market, By Type, From 2021 to 2026 (USD Billion)
  25. Middle East & Africa Autologous Cell-Based Products Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  26. Middle East & Africa Allogeneic Cell-Based Products Regenerative Medicines Market, By Region, From 2021 to 2026 (USD Billion)
  27. Middle East Cell-Based Products Regenerative Medicines Market, By Type, From 2021 to 2026 (USD Billion)
  28. Africa Cell-Based Products Regenerative Medicines Market, By Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample